Enliven Therapeutics has announced the pricing of its public offering, which aims to raise $400 million. The shares are set at a price of $37.50 each. This move is part of the company's strategy to enhance its financial position and support its ongoing research and development initiatives. The offering is expected to be completed shortly, subject to customary closing conditions.
Related Articles
Don't miss out on breaking stories and in-depth articles.